# Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

Source: https://onco.cc/trials/nct03600233/  
OnCo record `nct03600233` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of CVM-1118 in neuroendocrine tumours and pancreatic ductal adenocarcinoma, run by TaiRx, Inc., active and no longer recruiting.

## Summary

Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors is a phase 2 interventional study registered as NCT03600233 by TaiRx, Inc., with 34 participants enrolled, started 2018-12-15 and due to reach its primary completion in 2024-09-30. Interventions recorded: CVM-1118.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03600233
- Phase: 2
- Setting: A Phase II, Open-label Study of CVM-1118 Administered Orally to Patients With Advanced Neuroendocrine Tumors
- Sponsor: TaiRx, Inc.
- Enrolled: 34

## Sources

- ClinicalTrials.gov NCT03600233: https://clinicaltrials.gov/study/NCT03600233

## Connected records

- cancers: [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)

---
JSON: https://onco.cc/api/v1/entities/nct03600233.json